Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

      09:35 - 09:40  |  Presenter: Qing Zhou

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    P49 - Novel Therapeutics and Targeted Therapies - EGFR Major

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

      00:00 - 00:00  |  Presenter: Song Dong

      • Abstract

      Loading...

  • +

    P52 - Novel Therapeutics and Targeted Therapies - KRAS

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P52.02 - High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Hui-Bo Feng

      • Abstract

      Loading...

  • +

    P57 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - ICI Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P57.15 - Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Low Creatinine Clearance Rate

      00:00 - 00:00  |  Presenter: Jia-Yi Deng

      • Abstract

      Loading...

  • +

    ES11 - Small Cell Lung Cancer: Recent Preclinical Advances and Emerging Approaches to Therapy*

    • 11:15 - 11:50
    • 9/10/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Education Session
    • Track: Small Cell Lung Cancer/ NET
    *Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.
    • +

      ES11.03 - Emerging Strategies in ES-SCLC in the Frontline

      11:19 - 11:21  |  Presenter: Qing Zhou

      • Abstract

      Loading...

  • +

    WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer

    • 22:15 - 23:45
    • 9/11/2021
    • Location: Program Auditorium
    • Not for CME Credit
    • Type: Workshop
    • Track: N.A.
    • +

      WS06.06 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC

      23:03 - 23:13  |  Presenter: Song Dong

      • Abstract

      Loading...

    • +

      WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      23:13 - 23:23  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    OA16 - Clinical Impact of Liquid Biopsy for Patients with NSCLC

    • 20:00 - 21:00
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
    • +

      OA16.03 - Matched Targeted Therapy by cfDNA of CSF Beyond Leptomeningeal Metastases Progression Upon Osimertinib in EGFR-Mutated NSCLC Patients

      20:20 - 20:30  |  Presenter: Mei-Mei Zheng

      • Abstract

      Loading...